PMID- 34398265
OWN - NLM
STAT- MEDLINE
DCOM- 20210827
LR  - 20220426
IS  - 1432-1289 (Electronic)
IS  - 0020-9554 (Linking)
VI  - 62
IP  - 9
DP  - 2021 Sep
TI  - [Tumor vaccination-strategies and time points].
PG  - 991-997
LID - 10.1007/s00108-021-01138-2 [doi]
AB  - BACKGROUND: Immunotherapies have gained increasing importance in the treatment of 
      cancer in recent years. This also includes tumor vaccines, which are used 
      therapeutically to direct the immune system specifically against tumor cells. 
      OBJECTIVES: Different strategies of tumor vaccination, their current state of 
      development, the optimal timing and possible combinations of cancer vaccines in 
      the treatment of cancer are discussed. METHODS: Scientific publications on 
      various tumor vaccination strategies based on ongoing studies that are listed on 
      clinicaltrials.gov are summarized. CONCLUSIONS: For effective tumor vaccination, 
      the selection of suitable tumor antigens present on the cell surface via human 
      leukocyte antigen (HLA) molecules is essential. Suitable antigens should be 
      present exclusively on tumor cells and able to induce a specific anti-tumor 
      immune response, i.e. activate cytotoxic and T helper cells. For this purpose, 
      neoepitopes derived from tumor-specific mutations or tumor-associated antigens 
      (TAAs), which are present exclusively in tumor tissue due to altered gene 
      expression or processing, can be used. For the application of the antigens, 
      various strategies combined with suitable adjuvants are available, including 
      peptide vaccines, DNA- or RNA-based vaccines, approaches with dendritic cells or 
      whole tumor cell vaccines. Currently, numerous vaccination approaches as well as 
      combination protocols are being evaluated in clinical trials with the aim to 
      establish specific and low side effect immunotherapies to combat malignancies and 
      enable long-term protection from disease recurrence via the induction of 
      long-lasting antitumor immune responses.
CI  - (c) 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
FAU - Maringer, Yacine
AU  - Maringer Y
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, 
      Otfried-Muller-Str. 10, 72076, Tubingen, Deutschland.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Deutschland.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Deutschland.
FAU - Walz, Juliane S
AU  - Walz JS
AD  - Clinical Collaboration Unit Translational Immunology, German Cancer Consortium 
      (DKTK), Department of Internal Medicine, University Hospital Tubingen, 
      Otfried-Muller-Str. 10, 72076, Tubingen, Deutschland. 
      juliane.walz@med.uni-tuebingen.de.
AD  - Institute for Cell Biology, Department of Immunology, University of Tubingen, 
      Tubingen, Deutschland. juliane.walz@med.uni-tuebingen.de.
AD  - Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed 
      Tumor Therapies", University of Tubingen, Tubingen, Deutschland. 
      juliane.walz@med.uni-tuebingen.de.
AD  - Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch 
      Center for Tumor Diseases (RBCT), Stuttgart, Deutschland. 
      juliane.walz@med.uni-tuebingen.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Tumorvakzinierung -Strategien und Timing.
DEP - 20210816
PL  - Germany
TA  - Internist (Berl)
JT  - Der Internist
JID - 0264620
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigens, Neoplasm
MH  - *Cancer Vaccines
MH  - Humans
MH  - Immunotherapy
MH  - *Neoplasms/therapy
MH  - Vaccination
OTO - NOTNLM
OT  - Cancer vaccines
OT  - HLA antigens
OT  - Immunotherapy
OT  - Tumor antigen
OT  - T‑Lymphocytes
EDAT- 2021/08/17 06:00
MHDA- 2021/08/28 06:00
CRDT- 2021/08/16 12:59
PHST- 2021/08/02 00:00 [accepted]
PHST- 2021/08/17 06:00 [pubmed]
PHST- 2021/08/28 06:00 [medline]
PHST- 2021/08/16 12:59 [entrez]
AID - 10.1007/s00108-021-01138-2 [pii]
AID - 10.1007/s00108-021-01138-2 [doi]
PST - ppublish
SO  - Internist (Berl). 2021 Sep;62(9):991-997. doi: 10.1007/s00108-021-01138-2. Epub 
      2021 Aug 16.